Institutional Career Development Core
Institutional Career Development Core
批准号:
10731946
负责人:
John K. Amory
金额:
$18.22万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-06-01 至 2027-02-28
关键词:
AdultAgeAggressive behaviorBehaviorBehavior DisordersCaliforniaCandidate Disease GeneChildClinicalClinical TrialsCognition DisordersCognitiveDevelopmentDiseaseDown SyndromeElectrophysiology (science)EquationEvidence based interventionFamilyFundingFutureGenetic Predisposition to DiseaseImpairmentIndividualInstitutionIntellectual functioning disabilityInterventionInvestigationKnowledgeLaboratoriesLongevityMeasuresMentorshipMethodsModelingMutationNeuropsychologyPediatric HospitalsPopulationPrevalenceQualifyingQuality of lifeResearchResearch PersonnelRisk FactorsSamplingSeveritiesTrainingTranslational ResearchUniversitiesWashingtonacceptability and feasibilityautism spectrum disorderautistic childrenbehavioral phenotypingcareercareer developmentcohortexecutive functionexperiencemultidisciplinarymultimodalitynon-compliancenon-verbalprogramsskill acquisitionskillstranslational health scienceverbal
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE)
supplement will support a promising early career investigator, Hannah Rea, to broaden her research and
related clinical experience in behavioral and cognitive disorders co-occurring with Down syndrome. Among the
most common, quality-of-life impairing, and understudied behavioral phenotypes associated with Down
syndrome are challenging behaviors, such as aggression or noncompliance. Challenging behaviors have
negative long-term consequences for individuals with Down syndrome and their families, including contributing
to decreased acquisition of skills that are critical for global functioning and independence. The proposed
project aims to identify and analyze the interacting effects of risk factors for challenging behaviors in children
with Down syndrome, which will inform interventions.
This project will investigate nonverbal and verbal IQ as predictors of severity of challenging behaviors,
moderated by executive functioning in 120 children with Down syndrome ages 6 to 14 years. The feasibility
and acceptability of measures will be assessed with 10 families of children with Down syndrome and 5 adults
with Down syndrome and latent modeling and multi-modal measures will be used to operationalize EF and
challenging behaviors. The same models will be investigated in an archival sample of children with autism
spectrum disorder (ASD), a disorder that overlaps in commonly co-occurring conditions and occurs in
heightened prevalence in children with Down syndrome. The archival sample includes children with a known
genetic etiology associated with ASD with (n=125) or without (n=87) intellectual disability, and with a DYRK1A
mutation, a candidate gene for Down syndrome (n=27), ages 3 to 24 years. The comparison to ASD will inform
whether existing evidence-based interventions for children with ASD may be adapted for children with Down
syndrome.
Dr. Rea will join the Institute of Translational Health Sciences (based at the University of Washington)
as a KL2 scholar and receive mentorship from a highly qualified team of senior investigators at the University
of Washington, Seattle Children’s Hospital, and the University of California, Davis MIND Institute. Through the
KL2 program, Dr. Rea will gain knowledge and skills in translational science through interactive didactic
sessions with the multidisciplinary KL2 cohort. Additionally, Dr. Rea will seek intensive training in research with
children with Down syndrome and their families, electrophysiology methods with children, and advanced
statistical training in structural equation modeling. The proposed mechanism will support her progression
towards establishing her own laboratory and applying for independent research funding to support a future
clinical trial investigating the trajectory of and interventions for challenging behaviors in children with Down
syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ALDH1A1/A2 Inhibitors for Male Contraception
-
批准号:10430041
-
项目类别:
-
资助金额:$37.49万
-
财政年份:2019
-
负责人:John K. Amory
-
依托单位:
ALDH1A1/A2 Inhibitors for Male Contraception
-
批准号:10172963
-
项目类别:
-
资助金额:$37.49万
-
财政年份:2019
-
负责人:John K. Amory
-
依托单位:
ALDH1A1/A2 Inhibitors for Male Contraception
-
批准号:10651653
-
项目类别:
-
资助金额:$37.49万
-
财政年份:2019
-
负责人:John K. Amory
-
依托单位:
ALDH1A1/A2 Inhibitors for Male Contraception
-
批准号:10020794
-
项目类别:
-
资助金额:$38.26万
-
财政年份:2019
-
负责人:John K. Amory
-
依托单位:
Institutional Career Development Core
-
批准号:10711974
-
项目类别:
-
资助金额:$13.56万
-
财政年份:2017
-
负责人:John K. Amory
-
依托单位:
Institutional Career Development Core
-
批准号:10595040
-
项目类别:
-
资助金额:$122.65万
-
财政年份:2017
-
负责人:John K. Amory
-
依托单位:
Institutional Career Development Core
-
批准号:10524302
-
项目类别:
-
资助金额:$137.55万
-
财政年份:2017
-
负责人:John K. Amory
-
依托单位:
Institute of Translational Health Sciences
-
批准号:9474336
-
项目类别:
-
资助金额:$133.06万
-
财政年份:2017
-
负责人:John K. Amory
-
依托单位:
Retinoic Acid in Male Infertility
-
批准号:9230783
-
项目类别:
-
资助金额:$12.75万
-
财政年份:2015
-
负责人:John K. Amory
-
依托单位:
BDADs for Male Contraception
-
批准号:8049190
-
项目类别:
-
资助金额:$26.79万
-
财政年份:2009
-
负责人:John K. Amory
-
依托单位:
BDADs for Male Contraception
-
批准号:8427375
-
项目类别:
-
资助金额:$25.61万
-
财政年份:2009
-
负责人:John K. Amory
-
依托单位:
BDADs for Male Contraception
-
批准号:7770803
-
项目类别:
-
资助金额:$26.84万
-
财政年份:2009
-
负责人:John K. Amory
-
依托单位:
BDADs for Male Contraception
-
批准号:7863969
-
项目类别:
-
资助金额:$0.53万
-
财政年份:2009
-
负责人:John K. Amory
-
依托单位:
BDADs for Male Contraception
-
批准号:8230760
-
项目类别:
-
资助金额:$26.52万
-
财政年份:2009
-
负责人:John K. Amory
-
依托单位:
BDADs for Male Contraception
-
批准号:7626135
-
项目类别:
-
资助金额:$28.5万
-
财政年份:2009
-
负责人:John K. Amory
-
依托单位:
Oral Testosterone for Male Hormonal Contraception
-
批准号:7284591
-
项目类别:
-
资助金额:$43.0万
-
财政年份:2007
-
负责人:John K. Amory
-
依托单位:
ORAL ANDROGENS IN MAN-3: PK OF ORAL TESTOSTERONE BY ALPHA5-DUTASTERIDE
-
批准号:7603473
-
项目类别:
-
资助金额:$0.41万
-
财政年份:2007
-
负责人:John K. Amory
-
依托单位:
ORAL ANDROGENS IN MAN-4: GONADOTROPIN SUPPRESSION
-
批准号:7603511
-
项目类别:
-
资助金额:$0.49万
-
财政年份:2007
-
负责人:John K. Amory
-
依托单位:
ORAL ANDROGENS IN MAN-3: PK OF ORAL TESTOSTERONE BY ALPHA5-DUTASTERIDE
-
批准号:7379372
-
项目类别:
-
资助金额:$8.85万
-
财政年份:2006
-
负责人:John K. Amory
-
依托单位:
ORAL ANDROGENS IN MAN-2: PK OF ORAL TESTOSTERONE WITH 5 -REDUCTASE
-
批准号:7198860
-
项目类别:
-
资助金额:$7.42万
-
财政年份:2005
-
负责人:John K. Amory
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: